What do systematic reviews say?

Gemcitabine plus S‐1 vs S‐1

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs best supportive care

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus vandetanib vs vandetanib

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus folinic acid

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus oxaliplatin vs 5‐fluorouracil plus cisplatin plus radiotherapy

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine plus mitomycin C vs capecitabine plus mitomycin C

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Gemcitabine vs vandetanib

The review found no eligible studies for this question.

• Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Polymyxins vs aminoglycosides

The review found no eligible studies for this question.

• Head‐to‐head trials of antibiotics for bronchiectasis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings table (subcomparison 1): chemotherapy or targeted therapy plus best supportive care (BSC) vs BSC

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1129 participants
  Very low

Summary of findings table (subcomparison 2): second‐line chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 1638 participants
  Very low

Summary of findings table (subcomparison 3): chemotherapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  450 participants
  Very low

Summary of findings table (subcomparison 4): targeted therapy agent plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 2054 participants
  Very low

Summary of findings table (subcomparison 5): chemotherapy or targeted therapy agent(s) plus control intervention vs control intervention

• Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer 2017 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1870 participants
  Very low

External beam radiotherapy (EBRT) plus transarterial chemoembolisation (TACE) vs TACE alone

The review found no eligible studies for this question.

• External beam radiotherapy for unresectable hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Percutaneous ethanol injection vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Laser ablation vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Transarterial embolisation plus radiofrequency ablation vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Transarterial embolisation plus percutaneous alcohol injection vs percutaneous alcohol injection

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Surgery vs radiofrequency ablation

The review found no eligible studies for this question.

• Management of people with early‐ or very early‐stage hepatocellular carcinoma 2017 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

EGFR monoclonal antibody (cetuximab or nimotuzumab) plus standard therapy (radiotherapy or chemoradiotherapy) vs Standard therapy alone (radiotherapy or chemoradiotherapy)

• Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy 2015 · Cochrane All outcomes

  24 to 70 months
  Only one study (Bonner 2006, 424 participants) comprehensively assessed quality of life using EORTC QLQ-C30 (v3.0) and QLQ-H&N35; no statistically significant difference between groups for global health status or any…
  1 study · 424 participants
  GRADE not reported